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Background-—The usefulness of cardiovascular disease (CVD) predictive equations in different populations is debatable. We
assessed the efficacy of the Framingham-REGICOR scale, validated for the Spanish population, to identify future CVD in
participants, who were predefined as being at high-risk in the PREvencion con DIeta MEDiterranea (PREDIMED) study—a
nutrition-intervention primary prevention trial—and the impact of adherence to the Mediterranean diet on CVD across risk
categories.
Methods and Results-—In a post hoc analysis, we assessed the CVD predictive value of baseline estimated risk in 5966 PREDIMED
participants (aged 55–74 years, 57% women; 48% with type 2 diabetes mellitus). Major CVD events, the primary PREDIMED end
point, were an aggregate of myocardial infarction, stroke, and cardiovascular death. Multivariate-adjusted Cox regression was used
to calculate hazard ratios for major CVD events and effect modification from the Mediterranean diet intervention across risk strata
(low, moderate, high, very high). The Framingham-REGICOR classification of PREDIMED participants was 25.1% low risk, 44.5%
moderate risk, and 30.4% high or very high risk. During 6-year follow-up, 188 major CVD events occurred. Hazard ratios for major
CVD events increased in parallel with estimated risk (2.68, 4.24, and 6.60 for moderate, high, and very high risk), particularly in
men (7.60, 13.16, and 15.85, respectively, versus 2.16, 2.28, and 3.51, respectively, in women). Yet among those with low or
moderate risk, 32.2% and 74.3% of major CVD events occurred in men and women, respectively. Mediterranean diet adherence
was associated with CVD risk reduction regardless of risk strata (P>0.4 for interaction).
Conclusions-—Incident CVD increased in parallel with estimated risk in the PREDIMED cohort, but most events occurred in non–
high-risk categories, particularly in women. Until predictive tools are improved, promotion of the Mediterranean diet might be
useful to reduce CVD independent of baseline risk.
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T he current approach for cardiovascular disease (CVD)prevention uses risk estimation based on traditional
cardiovascular risk factors to tailor intervention accord-
ingly.1,2 There are different risk assessment models depend-
ing on the geographical area and the baseline risk of the
selected population.3 In European countries, the European
Society of Cardiology recommends the Systematic Coronary
Risk Evaluation (SCORE) strategy.4 Based on SCORE, many
surveys in different European countries have been performed
using either very simple5 or more complicated instruments.6,7
In Spain, a calibrated Framingham equation (Framingham-
REGICOR [F-R])8 shown to be effective in predicting CVD9,10 is
also commonly used.
These risk estimation systems are useful at a population
level but have limitations, in particular, a strong dependence
on age, short-term (10 year) risk prediction, reliance mostly
on a cross-sectional evaluation of risk, and no consideration
of nonclassical risk factors or current or past pharmacological
treatment (statin, antihypertensive, and antiplatelet
drugs).11,12 Of note, although the relative risk is always
higher in high-risk persons, most CVD events (55–80%) occur
in the low and moderate risk strata,10,13 a major problem for a
personalized risk reduction approach considering that usually
>75% of the population is classified as non–high risk.14,15
Consequently, the usefulness of these tools in different
settings and populations and its CVD predictive ability are still
a matter of debate.16
Despite the wide use of cardiovascular risk scores and the
progressive improvement in risk factor control, CVD is still the
leading cause of death and disability in developed coun-
tries.17,18 Newer strategies to better identify individuals at
risk and novel pharmacological and/or lifestyle treatment
approaches to prevent CVD events need to be developed. The
PREvencion con DIeta MEDiterranea (PREDIMED) trial demon-
strated that an affordable Mediterranean diet (MedDiet)
supplemented with foods rich in healthy fats (extra-virgin
olive oil [EVOO] and nuts) without aiming at weight change is
useful to prevent CVD in comparison with advice to follow a
low-fat diet.19 The baseline age (≥55 and ≥60 years for men
and women, respectively) and the high risk (either type 2
diabetes mellitus or ≥3 major cardiovascular risk factors) of
PREDIMED participants are of particular interest from an
epidemiological standpoint. First, some of the limitations of
predictive equations in current CVD prevention strategies11,12
could be partly overridden. Second, the clinically relevant
question of whether the MedDiet intervention tested in
PREDIMED was similarly effective regardless of baseline risk
could be assessed in a post hoc manner. We thus used the
prespecified high-risk PREDIMED cohort to assess baseline
cardiovascular risk and its association with future CVD, to test
the ability of recommended risk-estimation strategies to
identify persons who will suffer a CVD event during follow-up,
and to evaluate the effect of the intervention (MedDiet versus
low-fat diet) across the different estimated risk categories.
Material and Methods
Study Design and Participants
The PREDIMED study is a large, parallel-group, multicenter,
randomized, controlled, clinical trial designed to assess the
effects of the MedDiet on the primary prevention of CVD. The
design and primary results of the trial have been published in
detail.19,20 Briefly, from October 2003 to June 2009, a total of
8713 candidates were screened for eligibility at 11 recruiting
centers throughout Spain, and 7447 were randomly assigned
to 1 of 3 interventions: MedDiet supplemented with EVOO
(MedDiet/EVOO), MedDiet supplemented with mixed nuts
(MedDiet/nuts), or control diet (advice on a low-fat diet).
Participants were men aged 55 to 80 years and women aged
60 to 80 years at high cardiovascular risk but with no CVD at
enrollment. Criteria for eligibility were the presence of either
type 2 diabetes mellitus or at least 3 cardiovascular risk
factors: current smoking, hypertension, dyslipidemia, over-
weight or obesity, and family history of early onset coronary
heart disease. Participants were considered to have diabetes
mellitus, hyperlipidemia, or hypertension if they had a
previous diagnosis of these conditions and/or if they were
treated with antidiabetic, cholesterol-lowering, or antihyper-
tensive agents, respectively. Smoking status was categorized
into never, current, or past smoking, according to self-report.
Participants (n=5966, 57% women, 48% with type 2 diabetes
mellitus) who were aged <74 years (the age limit of the F-R
equation) with sufficient data to estimate their cardiovascular
risk were selected from the total cohort for the present
analyses (Figure 1). The study was conducted in accordance
with the Declaration of Helsinki. The institutional review board
of all recruiting centers approved the study protocol, and all
participants provided informed consent. The formal trial
protocol can be found in Data S1.
Variables and Procedures
Information regarding educational level (no studies or primary,
secondary or university studies) was recorded. A validated
137-item food-frequency questionnaire was used to estimate
food, nutrients, and total energy intake.21 The validated
Spanish version of the Minnesota Leisure Time Physical
Activity Questionnaire was used to estimate physical activ-
ity.22 Adherence to the MedDiet was assessed with a
validated 14-item dietary screener.23 Height, weight, and
waist circumference were measured with standard methods.
Fasting blood and spot urine were obtained at baseline and
yearly during follow-up. Plasma glucose, total cholesterol, high-
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density lipoprotein cholesterol, and triglycerides were mea-
sured by routine laboratory tests using standardized enzymatic
methods. Low-density lipoprotein (LDL) cholesterol was calcu-
lated with the Friedewald formula. Serum creatinine was
measured by enzymatic reaction using the Jaffe method, and
estimated glomerular filtration rate was calculated based on
creatinine using the CKD-EPI (Chronic Kidney Disease Epidemi-
ology Collaboration) equation.24 Urinary creatinine and albumin
concentrations were alsomeasured by the Jaffemethod and the
bromocresol green albumin method, respectively, and the
urinary albumin/creatinine ratio was calculated (mg/g).
Estimation of Cardiovascular Risk
Cardiovascular risk was estimated by the F-R strategy,8 which
uses a calibrated Framingham equation validated for Spain, a
low-risk country.10 This F-R index was calculated by using age,
sex, smoking habit, presence or absence of diabetes mellitus,
systolic and diastolic blood pressure, total cholesterol, and
high-density lipoprotein cholesterol.10 First, we identified
participants with ≥1 markedly elevated risk factor (LDL
cholesterol ≥240 mg/dL [n=12], systolic blood pressure
≥180 mm Hg and/or diastolic blood pressure ≥110 mm Hg
[n=397], or both criteria [n=4]). According to the F-R strategy,
these 409 participants were classified as at least high risk;
those with estimated risk ≥15%10 were classified as very high
risk. We defined risk categories as very high (all participants
with F-R ≥15%), high (a priori high risk or F-R 10–15%),
moderate (a priori non–high risk and F-R 5–10%), and low (a
priori non–high risk and F-R <5%) according to the F-R
equation. The flowchart of study participants is shown in
Figure 1. Cardiovascular risk was also estimated with the
stepped approach suggested in the European guidelines for
persons aged <65 years, the age limit defined in this
strategy.1 According to these guidelines, participants with
diabetes mellitus with ≥1 risk factor, microalbuminuria, or
chronic renal failure with an estimated glomerular filtration
rate ≤30 mL/min were classified as very high-risk (n=1162),
and those with diabetes mellitus without other cardiovascular
risk factors or microalbuminuria, an estimated glomerular
filtration rate between 30 and 60 mL/min, or ≥1 markedly
elevated conventional risk factor (total cholesterol >8 mmol/L
[300 mg/dL], systolic blood pressure ≥180 mm Hg or dias-
tolic blood pressure ≥110 mm Hg) were defined as high risk
(n=479) (Figure S1). For the remaining participants (n=1343),
cardiovascular risk was estimated with the SCORE equa-
tion for low-risk regions (uses age, sex, smoking habit,
systolic blood pressure, total cholesterol, and high-density
lipoprotein cholesterol),4 with values ≥10% representing very
high risk, 5% to 10% indicating high risk, 1% to 5% showing
moderate risk, and <1% noting low risk. The LDL cholesterol
thresholds according to estimated risk were defined as
Figure 1. Flow-chart of PREDIMED participants using Framingham-REGICOR strategy. CVR indicates
cardiovascular risk; LDL-C, low-density lipoprotein cholesterol.
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<130 mg/dL in participants at low risk, <115 mg/dL in those
at moderate risk, <100 mg/dL in those at high risk, and
<70 mg/dL in persons at very high risk.1
End Point Ascertainment
The main outcome was an aggregate of major adverse cardiac
events (MACE): myocardial infarction, defined by the presence
of symptoms suggestive of ischemia or infarction, with either
electrocardiographic evidence (new Q waves in ≥2 leads) or
cardiac-marker evidence of infarction, according to the
standard American College of Cardiology definition25; stroke,
defined as rapid onset of a neurological deficit lasting
>24 hours, supported by imaging studies (computed tomog-
raphy or magnetic resonance imaging scans); or death from
cardiovascular causes. Secondary outcomes (expanded
MACE) included MACE or revascularization (coronary bypass,
angioplasty, or thrombolytic procedures) and newly diagnosed
peripheral artery disease (defined as ankle-brachial index of
<0.9 at rest, clinical diagnosis of arterial occlusive disease
based on imaging tests, or endovascular or open surgical
procedure).26 Four sources of information were used to
ascertain end points: repeated contacts with participants,
contacts with family physicians, yearly review of medical
records, and consultation of the National Death Index. All
information on CVD events was evaluated by the end point
adjudication committee, whose members were blind to
treatment allocation. Only end points that were confirmed
by the adjudication committee and that occurred between
October 1, 2003, and December 1, 2010, were included in the
present analyses.19
Statistical Analyses
Data are presented as meanSD, median and interquartile
range, or number (percentage), unless otherwise indicated.
Normal distribution of continuous variables was assessed by
the Kolmogorov–Smirnov test. The j coefficient was used to
examine the agreement between risk-estimation strategies
(F-R and SCORE) in the classification of participants as high or
very high risk versus moderate or low risk. Differences in
clinical, anthropometric, sociodemographic, and laboratory
variables across the different categories of estimated risk
were evaluated by means of v2 or Kruskal–Wallis tests, as
appropriate. Differences in proportion of events (myocardial
infarction, stroke, death from cardiovascular causes, coronary
revascularization, or peripheral artery disease; merged MACE;
and expanded MACE) across risk categories were also
evaluated by v2 tests.
Follow-up time was calculated as the interval between the
date of randomization and the date of incident CVD, the date of
the last visit, or the last recorded clinical event of participants
still alive, whichever came first. Unadjusted and adjusted Cox
proportional hazard models were used to assess the associ-
ation between baseline estimated risk (both F-R and SCORE
strategies) and incident CVD (MACE and expanded MACE).
Adjustments were made for variables not included in the F-R
strategy: intervention group (low-fat diet versus merged
MedDiet/EVOO and MedDiet/nuts), baseline adherence to
the MedDiet, physical activity, total energy intake, educational
level, body mass index, baseline triglycerides, baseline diag-
nosis of hyperlipidemia, and treatment with antihypertensive
or statin drugs. Hazard ratios (HRs) and 95% CIs were
calculated, and the low-risk stratum was used as a reference
category. Finally, the effect of intervention (MedDiet as a
combination of MedDiet/EVOO and MedDiet/nuts) on CVD
was assessed across estimated cardiovascular risk strata (low,
moderate, high, very high) in Cox proportional hazards models,
both unadjusted and adjusted for the confounders mentioned
previously. The Benjamini–Hochberg false discovery rate was
used to adjust the main cardiovascular outcome results (HRs
for MACE and expanded MACE according to F-R risk strata and
for the effect of MedDiet) for multiple comparisons.27 The 2-
sided significance level was set at P<0.05. All analyses were
performed using the SPSS 20.0 statistical package (IBM Corp)
and SAS software, v.9.2 (SAS Institute Inc).
Results
Estimated Baseline Cardiovascular Risk
Baseline cardiovascular risk estimated by the F-R scale was
mostly moderate (44.5%), with 30% of participants classified
as high or very high risk (Figure 2). As expected, there were
sex differences in risk (P<0.001). More than 80% of women
were classified as being in the low/moderate risk category
and <2% were very high risk, whereas close to half of men
were high or very high risk and only 10% were classified as
low risk. The SCORE chart (n=2982) classified only 11 men
(<0.5%) as low risk, with most participants belonging to the
high or very high risk category (63% of the total cohort; 53% of
women and 75% of men) (Figure S2).
Concordance between the F-R and SCORE equations in
estimating cardiovascular risk was low (j=0.321), even after
excluding diabetic participants who were a priori categorized
as high or very high risk only in the SCORE model (j=0.441).
The SCORE charts classified more than twice as many
participants as high or very high risk compared with the F-R
model (Tables S1 and S2).
Treatment Goals and Cardiovascular Risk Factors
As expected (Table 1), LDL cholesterol, blood pressure, and
the proportion of active smokers increased across
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cardiovascular risk categories, with no remarkable sex
differences except in smoking prevalence, which was 4-fold
higher for men compared with women (31.4% versus 7.6%,
P<0.001) (Table S3). Likewise, the proportion of participants
with on-goal LDL cholesterol levels (56.5%, 34.3%, 15.5%, and
1.5%) and blood pressure <140/90 mm Hg (57.8%, 31.6%,
12.1%, and 10.1%) decreased from the lowest to the highest
risk categories (P<0.001, both) (Table 1). Even when consid-
ering a less strict LDL cholesterol target for the very high-risk
group (ie, <100 mg/dL), only 8.1% (10.3% of women, 7.8% of
men) met this goal. Overall, fewer women at high or very high
risk met LDL cholesterol or blood pressure goals or received
antiplatelet treatment compared with men (Table S3).
Table 2 shows the distribution of age, sex and selected
traditional and nontraditional cardiovascular risk factors. As
expected, variables considered in the F-R strategy worsened
across risk strata (P<0.001, all), with remarkably higher
prevalence of diabetes mellitus in participants classified as
very high risk (83% in the whole sample, 100% in women)
(Table S4). Waist circumference and the prevalence of
atherogenic dyslipidemia also increased from low to very high
risk (P<0.001, both). As shown in Table S4, the increment in
frequency of atherogenic dyslipidemia from low to very high
risk was more prominent in women compared with men: 2%
versus 64% and 3% versus 23%, respectively (P<0.001, both).
CVD Events by Estimated Cardiovascular Risk
There was low incidence of CVD events overall during the 6-
year follow-up period in both men (n=118) and women (n=70)
in this cohort of participants selected for a priori–defined high
risk (Table 3), ranging from 2.36 to 17.83 events per
1000 person-years in groups at low and very high risk,
respectively (Table 4). Low-risk women had an almost 3-fold
higher incidence of CVD events than low-risk men (2.66
versus 0.91 events per 1000 person-years, respectively). Men
and women at very high risk had a 20-fold (crude HR 20.22,
95% CI 2.76–148.09) and 4-fold (HR 4.45, 95% CI 1.26–
15.72) increased risk of CVD events, respectively, compared
with their low-risk counterparts. Compared with low-risk
Figure 2. Cardiovascular risk estimated by Framingham-REGICOR strategy in population aged 55 to
75 years in the total cohort (n=5966) (A), among women (n=3375) (B), and among men (n=2591) (C). Data
are shown as number and percentage.
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categories, women at moderate risk (HR 2.19, 95% CI 1.19–
4.05) and high risk (HR 2.51, 95% CI 1.21–5.21) had similar
risk of events, whereas high-risk men (HR 14.51, 95% CI
1.99–105.57) had almost double the risk of men at moderate
risk (HR 8.43, 95% CI 1.15–61.53). Adjustment for additional
risk factors not included in the F-R strategy slightly blunted
the strength of the associations (Table 4).
In men, the proportion of participants with a CVD event
(individually considered or merged in MACE or expanded
MACE) increased gradually (0.4%, 3.3%, 5.8%, and 8.4% with
low, moderate, high, and very high risk, respectively, for
MACE) across estimated F-R risk (Table 3 and Figure S3). In
women, this proportion was especially high in the very high
risk category, which represented only 1.7% (n=58) of female
participants; the exception was expanded MACE, which was
similar for high and very high risk due to peripheral artery
disease event distribution (2.2% and 1.7% in women at high
and very high risk, respectively). Even though the proportion
of participants who had a CVD event was higher in high-risk
categories, many events actually occurred in participants at
low or moderate risk, especially among women. Although in
men 32.2% of MACE occurred in those not at high risk (97.4%
of such MACE took place in the intermediate risk category),
74.3% of MACE occurred in non–high-risk women. These sex
differences were particularly apparent for cardiovascular
death (23.5% in non–high-risk men versus 85.7% in non–
high-risk women; P<0.001) (Table 3).
Effect of the MedDiet and Other Risk Factors on
CVD Incidence
The MedDiet (MedDiet/EVOO plus MedDiet/nuts versus low-
fat diet; DietGroup variable) had a protective effect (HR 0.72,
95% CI 0.54–0.97; P=0.0329) on CVD events, as reported
previously for the whole PREDIMED cohort.19 The benefits of
the MedDiet were similar across all estimated risk strata, for
both MACE and expanded MACE, and before and after taking
into account additional risk factors not included in the F-R
strategy (P>0.4 for DietGroup9REGICOR group interaction for
all comparisons) (Figure 3). In multivariate Cox proportional
hazards regression analysis, we found that in addition to
baseline F-R risk and diet group (HR 0.74, 95% CI 0.55–1.00;
P=0.053), baseline adherence to the MedDiet (HR 0.89, 95%
CI 0.82–0.96; P=0.002), presence of dyslipidemia (HR 1.77,
95% CI 1.16–2.69; P=0.008), treatment with statins (HR 0.47,
95% CI 0.30–0.75; P=0.001), and triglyceride concentration
(HR 1.002, 95% CI 1.00–1.004; P=0.069) were independently
associated with MACE, with similar results by sex.
Discussion
In this study, the recommended strategies to evaluate
cardiovascular risk1,2 classified two-thirds of participants
from an a priori–defined high-risk Mediterranean cohort as
non–high risk. The cohort was selected based on participant









Risk (n=475) P Value
LDL-C
LDL-C, mg/dL 12634 13033 13435 14234 <0.001
Statin use, n (%) 709 (47.3) 1117 (42.1) 477 (35.7) 115 (24.2) <0.001
Meeting LDL-C
goals, n (%)
841 (56.5) 905 (34.3) 203 (15.5) 7 (1.5) <0.001
BP
SBP, mm Hg 137.515.7 14614.9 161.120.5 158.217.6 <0.001
DBP, mm Hg 80.09.2 83.19.2 86.711.3 85.59.5 <0.001
Use of antihypertensive
drugs, n (%)
1138 (76.0) 1978 (74.5) 1023 (76.6) 352 (74.1) 0.424
BP <140/90, n (%) 867 (57.8) 838 (31.6) 161 (12.1) 48 (10.1) <0.001
Smoking status




228 (15.2) 504 (19.0) 271 (20.3) 111 (23.4) <0.001
Data expressed as meanSD or n (%). LDL-C goals according to estimated cardiovascular risk were defined as <130 mg/dL for low risk, <115 mg/dL for moderate risk, <100 mg/dL for
high risk, and <70 mg/dL for very high risk. BP indicates blood pressure; DBP, diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure.
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age (55–74 years) and high prevalence of cardiovascular risk
factors (82% hypertension, 74% dyslipidemia, and 48% with
type 2 diabetes mellitus). This finding should not discourage
health care professionals from using these guidelines as a
first step for population-based CVD prevention strategies.
Indeed, baseline risk estimated by the F-R strategy had good
predictive power, with relative risks for major CVD events
increasing 2.7-, 4.2-, and 6.6-fold for moderate, high, and very
high-risk participants, respectively, compared with those at
low risk. However, even though the number of CVD events
increased with estimated cardiovascular risk, most events
actually occurred in non–high-risk participants, which concurs
with prior reports from other populations.10,13 This finding
was particularly true in women, for which only 25% of total
and 15% of fatal CVD events occurred in the groups at high or
very high risk (Table 3).
In the PREDIMED cohort, cardiovascular risk estimated
with the F-R equation was mostly moderate (44.5%), with only
8% of participants identified as very high risk (Figure 2).
Prevalent CVD is the main determinant of future events1,28
and explains most of the very high-risk category in population-
based studies.14 However, even in the setting of this primary
CVD prevention trial, the high proportion of non–high-risk
persons is somewhat surprising, given the participants’
characteristics, namely, 50% with diabetes mellitus and/or
≥3 cardiovascular risk factors. Indeed, the baseline cardio-
vascular risk distribution was similar to that observed in a
nonselected nationwide population-based sample.14 This may
be due to the fact that 40% of PREDIMED participants were
treated with statins and 74% received antihypertensive
agents, thus blunting the potency of cholesterol concentra-
tions and blood pressure—critical factors used to evaluate









Age, y 65.85.2 64.84.8 65.94.7 67.44.8 <0.001
Men, n (%) 263 (17.6) 1129 (42.5) 782 (58.5) 417 (87.8) <0.001
Total cholesterol, mg/dL 207.437.0 204.835.7 208.837.6 217.634.7 <0.001
HDL-C, mg/dL 59.311.8 49.89.8 46.99.1 42.58.4 <0.001
Diabetes mellitus, n (%) 262 (17.5) 1322 (49.8) 888 (66.5) 394 (83.0) <0.001
Microalbuminuria ≥30 mg/g, n (%)* 42 (9.3) 115 (12.6) 116 (22.2) 53 (27.9) <0.001
eGFR (CKD-EPI, mL/min)† 75.715.8 77.415.8 77.316.0 76.314.2 0.010
BMI, kg/m2 29.63.8 30.23.9 30.33.8 30.04.0 <0.001
Waist, cm 97.110.5 100.610.0 102.710.1 104.19.8 <0.001
Obesity, n (%) 650 (43.4) 1302 (49.0) 669 (50.1) 219 (46.1) <0.001
Central obesity‡ 1053 (71.1) 1815 (69.5) 897 (68.4) 279 (60.3) <0.001
Triglycerides, mg/dL 98.3 (75.9–129.7) 117.8 (90.5–155.9) 129.9 (97.2–172.7) 153.7 (111.2–216.0) <0.001
Atherogenic dyslipidemia, n (%)§ 33 (2.2) 277 (10.5) 201 (15.3) 133 (28.0) <0.001
Physical activity (METS) 210.0213.9 234.5241.0 261.9277.6 271.8265.4 <0.001
Baseline adherence to MedDiet (points) 8.81.9 8.71.9 8.61.9 8.72.1 0.140
Allocation to MedDiet groups, n (%) 1009 (67.3) 1836 (69.1) 899 (67.3) 318 (66.9) 0.492
Education level (%)
No studies or primary 1192 (79.5) 2018 (76.0) 998 (74.7) 343 (72.2) 0.020
Secondary 207 (13.8) 433 (16.3) 228 (17.1) 90 (19.0)
University 100 (6.7) 205 (7.7) 110 (8.2) 42 (8.8)
Data expressed as meanSD, median (interquartile range), or n (%) unless indicated otherwise. In bold the variables used to estimate cardiovascular risk in Framingham-REGICOR strategy.
BMI indicates body mass index; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol;
MedDiet, Mediterranean diet; METS, metabolic equivalent.
*Information available for 450, 912, 523, and 190 participants at low, moderate, high, and very high risk, respectively.
†eGFR based on CKD-EPI creatinine equation. Information available for 1105, 1896, 967, and 348 participants at low, moderate, high, and very high risk, respectively.
‡Central obesity was defined as waist >88 cm for women and >102 cm for men. Information was missing for 100 participants.
§Atherogenic dyslipidemia was defined as HDL-C <40 mg/dL and triglycerides >150 mg/dL in men and HDL-C <45 mg/dL and triglycerides >150 mg/dL in women. Information was
missing for 28 participants.
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cardiovascular risk. Furthermore, cholesterol and blood
pressure goals are set according to estimated risk, and
partial success in achieving these goals might help explain the
residual risk beyond pharmacological treatment and why most
events in the PREDIMED cohort occurred in non–high-risk
participants.







Participants, n (%) 1236 (36.6) 1527 (45.2) 554 (16.4) 58 (1.7) 3375 (100)
Estimated CVR 3.20.8 6.41.4 9.82.7 16.72.2 6.03.1
MI, n 1 14 5 2 22
Events in risk strata, % 0.1 0.9 0.9 3.5* 0.7
Total events, % 4.6 63.6 22.7 9.1 100
Stroke, n 11 19 11 2 43
Events in risk strata, % 0.9 1.2 2.0 3.5 1.3
Total events, % 25.6 44.2 25.6 4.7 100
CVD death, n 5 7 1 1 14
Events in risk strata, % 0.4 0.5 0.2 1.7 0.4
Total events, % 35.7 50.0 7.14 7.14 100
MACE, n 14 38 15 3 70
Events in risk strata, % 1.1 2.5 2.7 5.2† 2.1
Total events, % 20.0 54.3 21.4 4.3 100
Expanded MACE, n 22 54 31 3 110
Events in risk strata, % 1.8 3.5 5.6 5.2* 3.3
Total events, % 20.0 49.1 28.2 2.7 100
Men
Participants, n (%) 263 (10.2) 1129 (43.6) 782 (30.2) 417 (16.1) 2591 (100)
Estimated CV risk 3.70.7 7.01.4 11.21.8 18.83.9 9.85.0
MI, n 0 20 21 11 52
Events in risk strata, % 0 1.8 2.7 2.6† 2.0
Total events, % 0 38.5 40.4 21.1 100
Stroke, n 1 13 20 15 49
Events in risk strata, % 0.4 1.2 2.6 3.6* 1.9
Total events, % 2.0 26.5 40.8 30.6 100
CVD death, n 0 8 10 16 34
Events in risk strata, % 0 0.7 1.3 3.8* 1.3
Total events, % 0 23.5 29.4 47.1
MACE, n 1 37 45 35 118
Events in risk strata, % 0.4 3.3 5.8 8.4* 4.6
Total events, % 0.9 31.4 38.1 29.7 100
Expanded MACE, n 3 60 80 51 194
Events in risk strata, % 1.1 5.3 10.2 12.2* 7.5
Total events, % 1.6 30.9 41.2 26.3 100
Data expressed as meanSD or n (%) unless otherwise indicated. MACE is defined as MI, stroke, or cardiovascular death. Expanded MACE is MACE plus coronary revascularization or
peripheral arterial disease. CVD indicates cardiovascular disease; CVR, cardiovascular risk; MACE, major adverse cardiac event; MI, myocardial infarction.
*P<0.01 between groups.
†P<0.05 between groups.
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Cholesterol-lowering therapy, in particular, statins, is one
of the most important strategies to reduce cardiovascular
risk.29 Nevertheless, a low proportion of participants achieved
LDL cholesterol goals in our cohort; for instance, only 23.6%
of those at high or very high risk had LDL cholesterol
<100 mg/dL. This observation concurs with findings of the
European Action on Secondary and Primary Prevention by
Intervention to Reduce Events (EUROASPIRE) IV study,30 in
which <20% of coronary patients had LDL cholesterol
<70 mg/dL. This underscores the fact that poor achievement
of LDL cholesterol and blood pressure goals is common in
cardiovascular risk prevention across different European
countries.30 Statin use, which was relatively low in our cohort
(40%), could partly explain the lack of LDL cholesterol goal
attainment. The high proportion of participants (more than
two-thirds of the sample) (Figure 2) with low or moderate F-R
risk in our primary CVD prevention cohort31 could partly
explain this observation. Yet a similar proportion of (a priori
high-risk) participants with type 2 diabetes mellitus from a
large (n=28 6791) Mediterranean cohort received statin
treatment (41%) despite the fact that 18% had prior CVD.32
Although male sex is a well-established risk factor,33 the
proportion of deaths from cardiovascular causes is similar
among European men and women (35% and 36%, respectively)
aged <75 years.18 Concurring with prior studies,14,34 the
prevalence of high or very high risk among women was half
that found in men (18% versus 36%), even though women
were older by study design. Consequently, the higher
incidence of CVD events (MACE and expanded MACE) in
men compared with women was not unexpected. Neverthe-
less, it is noteworthy that while 2 of 3 CVD events in men took
place in those at high or very high risk, <25% events in women
occurred in those at high or very high risk. Sex differences in
CVD events in the low risk category were also noticeable
because only 1.6% of events in men, compared with 20% of
events in women, occurred in the low risk category.
Compared with low-risk strata, adjusted HRs rose in parallel
with risk in men (7.60-, 13.16-, and 15.85-fold for moderate,
high, and very high risk, respectively) but not in women (2.16-,
2.28-, and 3.51-fold for moderate, high, and very high risk,
respectively) (Table 4). Clearly, our risk classification strategy
performed worse in women than in men, confirming a prior
observation in a population-based study.10 These results
support the proposal of the American Heart Association to
address CVD-preventive strategies specifically accounting for
sex differences both in the general population35 and in
persons with diabetes mellitus.36
The fact that many CVD events occur in men and women at
low or moderate risk needs to be emphasized. Identification of
additional risk factors and evaluation of their contribution to
CVD is necessary to both to improve our prediction strategies,
based mainly on traditional risk factors, and to better tailor
preventive interventions at the individual and population
levels.37 Results of noninvasive vascular imaging techniques
have been shown to improve cardiovascular risk prediction.38
Newer evidence from large genetic studies39,40 indicates that
Table 4. HRs of Major Cardiovascular Events (Myocardial Infarction, Stroke, or Cardiovascular Death) According to Estimated




Person-Years) Unadjusted HR P Value Fully Adjusted HR* P Value
Total Low risk 2.36 1 (reference)  1 (reference) 
Moderate risk 6.39 2.81 (1.61–4.89) <0.001† 2.68 (1.53–4.69) <0.001†
High risk 10.23 4.58 (2.59–8.06) <0.001† 4.24 (2.39–7.54) <0.001†
Very high risk 17.83 7.95 (4.36–14.49) <0.001† 6.60 (3.55–12.30) <0.001†
Women Low risk 2.66 1 (reference)  1 (reference) 
Moderate risk 5.58 2.19 (1.19–4.05) 0.012† 2.16 (1.16–4.04) 0.015†
High risk 6.14 2.51 (1.21–5.21) 0.014† 2.28 (1.07–4.89) 0.034
Very high risk 12.27 4.45 (1.26–15.72) 0.020† 3.51 (0.92–13.35) 0.066
Men Low risk 0.91 1 (reference)  1 (reference) 
Moderate risk 7.51 8.43 (1.15–61.53) 0.036 7.60 (1.04–55.57) 0.046
High risk 13.15 14.51 (1.99–105.57) 0.008† 13.16 (1.80–95.92) 0.011†
Very high risk 18.55 20.22 (2.76–148.09) 0.003† 15.85 (2.14–117.20) 0.007†
*REGICOR (age, sex, smoking, total cholesterol, high-density lipoprotein cholesterol, blood pressure, and diabetes mellitus) was additionally adjusted for group (Mediterranean diet vs low-
fat diet), baseline adherence to a Mediterranean diet, educational level, body mass index, triglycerides, treated hypertension, dyslipidemia, statin treatment, and physical activity. HR
indicates hazard ratio.
†P values less than or equal to a false discovery rate of q=0.024 show significant results (see Statistical Analyses).
DOI: 10.1161/JAHA.116.004803 Journal of the American Heart Association 9


















 http://ahajournals.org by on M
ay 13, 2020
triglycerides, the culprit of atherogenic dyslipidemia,41 is
causally related to future CVD events, and triglyceride
lipoprotein content has been associated with preclinical
atherosclerosis.42 Triglycerides, as well as high-density
lipoprotein cholesterol, may contribute to residual cardiovas-
cular risk beyond LDL cholesterol levels.43,44 No detailed
lipoprotein composition studies were performed in the
PREDIMED cohort, but the triglyceride levels tended to be
independently associated with CVD events. More interesting,
adherence to the MedDiet not only was associated with lower
incidence of CVD at baseline or as a consequence of the
intervention but also was beneficial regardless of the
estimated cardiovascular risk. Consequently, implementation
of the MedDiet appears to be a useful strategy to promote
cardiovascular health at both the individual and population
levels, independent of baseline risk.
The main strengths of our study are the large sample size
(n=5966), the close follow-up during the trial, and the rigorous
certification of CVD events by an independent end point
adjudication committee. In addition, a novel aspect of this work
is the use of an a priori–defined high-risk PREDIMED population
with high prevalence of treated cardiovascular risk factors (and
thus with values of blood pressure or lipid profile largely
affected by cardioprotective treatment). Cohorts such as ours
are usually underrepresented in studies using predictive risk
equations. Our study also has limitations. Because the calcu-
lation of total risk by the F-R strategy is in part limited
(equation restriction) to persons aged 35 to 74 years, our
Figure 3. Hazards ratios of cardiovascular disease events of merged MedDiet/EVOO and MedDiet/nuts across estimated cardiovascular risk
categories by the Framingham-REGICOR strategy. Unadjusted (A) and fully adjusted (B) models for major cardiovascular events (acute
myocardial infarction, stroke, and cardiovascular death). Unadjusted (C) and fully adjusted (D) models for expanded major cardiovascular events
(with addition of cardiac revascularization and peripheral arterial disease). B and D, Additionally adjusted for baseline adherence to the MedDiet,
educational level, body mass index, triglycerides, treated hypertension, dyslipidemia, statin treatment, and physical activity. P values less than or
equal to a false discovery rate q=0.024 show significant results (see Statistical Analyses). EVOO indicates extra-virgin olive oil; HR, hazard ratio;
MedDiet, Mediterranean diet.
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results cannot be extended to those aged >74 years. In
addition, because of the prespecified baseline high prevalence
of major cardiovascular risk factors, the results are not
generalizable to populations with lower baseline risk.
In conclusion, most participants in the PREDIMED cohort,
prespecified as being at high cardiovascular risk, were
classified as non–high risk with the F-R scale, a population
risk-assessment scale validated in Spain.8,10 As expected,
major CVD events increased in parallel with estimated risk.
However, the observation that nearly 1 of 3 events in men and
3 of 4 events in women occurred in persons classified as non–
high risk points to the limitations of this population-based
strategy. CVD risk prediction would probably be improved
with consideration of other risk factors not currently included
in the equations and of circulating and vascular imaging
biomarkers.38,42 Pending refinement of cardiovascular risk
estimation for this new personalized and predictive medicine,
our finding that adherence to the MedDiet reduces the CVD
burden across all risk categories adds to accumulating
evidence of the benefit of this dietary pattern as a useful
population-based approach for CVD prevention.19,45,46
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